The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation

Completed · Phase 2/Phase 3

Conditions studied: Patients Active and Listed for Lung Transplantation

In brief

The purpose of this study is to compare outcomes in patients undergoing lung transplantation, using 2 different induction therapies. Primary outcome is survival and secondary outcomes include freedom from infection and freedom from rejection.

Key facts

Study ID

NCT00181142

Run by

Johns Hopkins University

People needed

60

Starts

1999-10-01

Expected to finish

2004-12-01

Last updated by the study team

2017-12-26

Who can join

Age: 18 and older, up to 66. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients accepted and listed for lung transplantation will be considered for randomization

You may not qualify if…

• Patients who demonstrate hemodynamic instability, requiring inotropes for greater than 48 hours prior to transplant
• Severe reperfusion pulmonary edema or primary graft dysfunction requiring FiO2 of > 50% and PEEP > 10 cm for greater than 48 hours prior to transplant
• Preoperative renal insufficiency (CrCl < 50 gm.d or serum creatinine > 2.0)
• Pre-operative panel reactive antibodies PRA
• Preoperative recipient bacterial or fungal colonization
• Preoperative antimicrobial suppressive therapy

Where it is running

• Johns Hopkins University Hospital — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.